WASHINGTON TRUST Co acquired a new stake in Solventum Co. (NYSE:SOLV – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,188 shares of the company’s stock, valued at approximately $63,000.
Other hedge funds have also recently bought and sold shares of the company. Fifth Lane Capital LP purchased a new position in Solventum in the 1st quarter valued at approximately $826,000. Boit C F David acquired a new stake in Solventum in the 1st quarter valued at about $152,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in shares of Solventum in the 1st quarter valued at about $5,747,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Solventum in the first quarter valued at $209,000. Finally, LRI Investments LLC purchased a new stake in Solventum during the 1st quarter worth about $43,000.
Solventum Trading Up 0.9 %
Shares of NYSE:SOLV traded up $0.53 during trading on Tuesday, reaching $58.24. The company had a trading volume of 773,811 shares, compared to its average volume of 2,163,123. The company has a current ratio of 1.31, a quick ratio of 0.96 and a debt-to-equity ratio of 2.90. The firm’s fifty day moving average price is $54.13. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on the stock. The Goldman Sachs Group increased their target price on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research report on Monday. Bank of America dropped their price objective on Solventum from $70.00 to $60.00 and set a “neutral” rating on the stock in a report on Tuesday, June 25th. Argus started coverage on Solventum in a report on Monday, June 24th. They issued a “hold” rating for the company. Morgan Stanley dropped their price target on Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Finally, Wells Fargo & Company decreased their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. According to MarketBeat.com, Solventum currently has a consensus rating of “Hold” and an average price target of $58.25.
Get Our Latest Stock Report on SOLV
Solventum Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Recommended Stories
- Five stocks we like better than Solventum
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- How to Use the MarketBeat Excel Dividend Calculator
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.